Development of blood-based monitoring techniques in lymphatic malignancies

Development of blood-based monitoring techniques in lymphatic malignancies - BioLymph

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47352

Enrollment

300

Registered

2017-03-14

Start date

2017-05-01

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoide maligniteiten volgens WHO 2016 classificatie lymphatic malignancies

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Diagnosed with a lymphoid malignancy as defined in the WHO classification 2016.

Exclusion criteria

Exclusion criteria: Patient is at inclusion also diagnosed with a solid-malignancy, such as breast cancer, colon carcinoma, melanoma or other solid malignancies that requires treatment.

Design outcomes

Primary

Measure	Time frame
The main study endpoint is the development of validated blood-based assays for monitoring disease status in patients with lymphoid neoplasms and correlation of blood-based assays with PET response during and after treatment.	—

Countries

Netherlands

Outcome results